Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...
InvestorsHub on MSN
Aptevo shares drop despite encouraging AML trial results
Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...
Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results